

Reviewer Relationships with Industry and Other Entities (Comprehensive) — 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants

| Committee Member | Employment | Consultant | Speakers Bureau | Ownership /Partnership/ Principal | Research/Research Grants | Institutional, Organizational, or Other Financial Benefit | Expert Witness |
|-------------------------|--|--|------------------------|--|---------------------------------|--|--|
| Niti R. Aggarwal | Mayo Clinic, Rochester, Minnesota— Assistant Professor of Medicine | None | None | None | None | None | None |
| Kim K. Birtcher | University of Houston College of Pharmacy—Clinical Professor | Jones and Bartlett Learning | None | None | None | None | None |
| Linda A. Briggs | George Washington University— Associate Professor | None | None | None | None | National Quality Forum (n) | None |
| Gregory J. Dehmer | Carilion Clinic, Cardiology and Carilion Cardiovascular Institute— Medical Director, Quality and Outcomes; Virginia Tech Carilion School of Medicine | CMS MedCAC Panel Member ; FDA Circulatory System Devices Panel of the Medical Devices Advisory Committee | None | None | None | Society for Cardiovascular Angiography and Interventions (n) | None |
| Timothy A. Dewhurst | Washington Permanente Medical Group— Interventional | None | None | None | None | Group Health Permanente, (n) | Defendant, Informed Consent for anti-coagulation medication, 2019; |

| | | | | | | | |
|------------------------|---|---|---|------|--|---|--|
| | Cardiologist and Medical Director of Clinical Value Improvement | | | | | | Defendant, procedural complications of purported valve injury after ablation, 2019 |
| Michael S. Firstenberg | Northeast Ohio Medical Universities— Associate Professor of Surgery and Integrative Medicine; Summa Akron City Hospital— Cardiothoracic Surgeon | ALLMED (s); Johnson and Johnson/ Ethicon (s); Medtronic (s); Specialty Care (n) | None | None | Destiny Pharma (DSMB) | None | |
| Bulent Gorenek | Eskisehir Osmangazi University Cardiology Department, Eskisehir-Turkey— Professor of Medicine | None | Bayer; Boehringer Ingelheim; Daiichi Sankyo; Pfizer; Sandoz | None | None | None | None |
| Martha Gulati | University of Arizona College of Medicine—Chief of Cardiology | None | None | None | None | None | None |
| Eileen M. Handberg | Shands Hospital at the University of Florida—Associate Professor of Medicine | Bristol-Myers Squibb Company | None | None | Astrom Biosciences (s); Amorceyte (s); Biocardia (s); Brigham and Women's Hospital (s); Capricor (s); Cytori Therapeutics, | Amgen; AstraZeneca; Boehringer Ingleheim; Daiichi Sankyo; Gilead Sciences; Ionis; Relypsa | None |

| | | | | | | | |
|-----------------|--|--|---------|------|--|--|------|
| | | | | | (s); Department of Defense (s); Direct Flow Medical (s); Duke Clinical Research Institute (s); East Carolina University (s); Everyfit (s); Medtronic (s); Merck (s); Mesoblast (s); NIH (s); NIH through Brigham and Women's Health (s); NIH through University of Rochester (s); NIH through University of Texas (s); PCORI (s); Sanofi Aventis (s) | | |
| Kousik Krishnan | Rush University Medical Center— Associate Professor of Medicine and Pediatrics; Director, Clinical Cardiac Electrophysiology Fellowship Program; Director, Arrhythmia Device Clinic | Bristol-Myers Squibb; Janssen; Zoll | Janssen | None | None | Abbott‡ Boston Scientific (s); MEDTRONIC (s); St. Jude Medical (s) St. Jude‡ | None |

| | | | | | | | |
|----------------------|--|------------------------------------|------|-------------------------------|---|--|------|
| Joseph Edward Marine | Johns Hopkins University School of Medicine—Associate Professor of Medicine | American College of Cardiology (s) | None | None | UpToDate (DSMB) | | None |
| Geno J. Merli | Thomas Jefferson University Hospital—Associate Professor of Medicine; Ludwig Kind Professor of Medicine; Director, Jefferson Center for Vascular Disease | LowRisk (n) | None | None | BMS-Pfizer (n); Janssen (n); Portola | None | None |
| Harry B. Peled | St Jude Medical Center—Medical Director of Cardiology and Critical Care | None | None | None | None | None | None |
| Andrea L. Price | Indiana University Health—Director, Quality Databases | None | None | Quality Informatics Synergies | American College of Cardiology Accreditation Foundation Board (s) | None | None |
| Andrea M. Russo | Cooper Medical School of Rowan University—Professor of Medicine; Director, Cardiac Electrophysiology and Arrhythmia Services; Director, CCEP Fellowship Cooper University Hospital | | None | None | None | Apple (n); Boehringer Ingelheim‡; Boston Scientific (n); Boston Scientific‡; Kaestra‡; MediLynx‡; Up-To-Date | None |

| | | | | | | | |
|---------------------|--|--|---------|------|------|------|------|
| Win-Kuang Shen | Mayo Clinic Arizona - Phoenix Campus— Consultant and Chair, Department of Cardiovascular Diseases; Professor of Medicine; Mayo Clinic College of Medicine, Rochester— Professor of Medicine | None | None | None | None | None | None |
| Sarah A. Spinler | Binghamton University— Professor and Chair, Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences | None | Portola | None | None | None | None |
| Karol E. Watson | David Geffen School of Medicine at UCLA —Professor of Medicine/Cardiology ; Co-director, UCLA Program in Preventive Cardiology; Director, UCLA Barbra Streisand Women's Heart Health Program | Amarin Amgen; Boehringer Ingelheim (s); Esperion | None | None | None | None | None |
| David E. Winchester | University of Florida College of Medicine (UFCOM)—Associate Professor of | None | None | None | None | None | None |

| | | | | | | | |
|---|--|--|--|--|--|--|--|
| Medicine; Malcom Randall VAMC—Staff Cardiologist; Assistant Cardiology Fellowship Program Director, Quality and Research; Co-Director, Advanced Fellowship for Cardiovascular Imaging; Co-Director, University of Florida (UF) Health Cardiac Imaging Group | | | | | | | |
|---|--|--|--|--|--|--|--|

This table represents all relationships of committee members with industry and other entities that were reported by authors, including those not deemed to be relevant to this document, at the time this document was under development. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥\$5,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Please refer to <http://www.acc.org/guidelines/about-guidelines-and-clinicaldocuments/relationships-with-industry-policy> for definitions of disclosure categories or additional information about the ACC/AHA Disclosure Policy for Writing Committees.

(n) No financial benefit.

(s) Significant relationship.

‡ Relationship with this company is limited to enrolling patients in clinical trials. This disclosure was entered under the Clinical Trial Enroller category in the ACC’s disclosure system. To appear in this category, the author acknowledges that there is no direct or institutional relationship with the trial sponsor as defined in the ACC/AHA Disclosure Policy for Writing Committees.

BMS=Bristol-Myers Squibb; CMS=Centers for Medicare and Medicaid Services; DSMB=Data Safety Monitoring Board; FDA=Food and Drug Administration; MedCAC=Medicare Evidence Development & Coverage Advisory Committee; NIH=National Institutes of Health; PCORI= Patient-Centered Outcomes Research Institute.